The clinical meaning of the "indefinite for atrophy" lesions within gastric mucosa biopsy specimens in a region with a high prevalence of gastric cancer.

Abstract

The diagnosis of gastric atrophy is important in the regions where the prevalence of Helicobacter pylori (H. pylori) is high. The assessment of gastric atrophy is impossible in subjects with severe gastric inflammation or inadequate biopsy samples, leading these cases to be categorized as indefinite for atrophy. The aim of this study was to evaluate clinical characteristics of cases reported as indefinite for atrophy. We reviewed 3192 gastric biopsies obtained at a single medical center between 2003 and 2017. Cases categorized as indefinite atrophy (n=1,292) were compared with three groups, the absent atrophy group (n=755), Operative Link on Gastric Atrophy (OLGA) I-II group (n=925), and OLGA III-IV group (n=220), by considering age, sex, smoking, alcohol drinking, salty and spicy food diet, ABO blood type, family history of gastric cancer (GC), and H. pylori infection that are known atrophic gastritis-associated risk factors. Subjects aged ≥65years (34.9% vs 26.4%, P<0.001), male (58.9% vs 49.1%, P<0.001), and H. pylori infected subjects (82.5% vs 63.3%, P<0.001) were significantly more likely to be categorized into the indefinite atrophy group than absent atrophy group. Subjects with family history of GC (21.9% vs 25.7%, P=0.031) and positive H. pylori infection (82.5% vs 86.2%, P=0.019) were significantly less likely to be in the indefinite atrophy group than low-risk OLGA group. Subjects aged ≥65years (34.9% vs 52.3%, P<0.001) and current/past smoker (50.9% vs 70.0%, P<0.001) were significantly more likely to be in the high-risk OLGA group than indefinite atrophy group. The pathological report of indefinite for atrophy suggests a higher plausibility of gastric atrophy than nonassessment due to a simple technical error.